Janssen&Janssen schreef op 15 april 2024 21:21:
Onderstaande bewust achter gehouden door sommige??
Fourth Quarter and Full Year 2023 Financial Results
Liquidity Position. Cash and cash equivalents were approximately €391 million as of December 31, 2023, compared to approximately €162 million for December 31, 2022.
Research and Development (R&D) Expenses. R&D expenses were €18.6 million for the fourth quarter and €65.6 million for the full year of 2023, compared to €15.7 million for the fourth quarter and €57.4 million for the full year of 2022.
General and Administrative (G&A) Expenses. G&A expenses were €8.6 million for the fourth quarter and €31.3 million for the full year of 2023, compared to €7.8 million for the fourth quarter and €29.3 million for the full year of 2022.
Loss for the year. Loss for the fourth quarter of 2023 was €32.7 million, resulting in basic and diluted loss per share of €0.74. For the full year of 2023, loss was €101 million, resulting in basic and diluted loss per share of €2.63 per share. This compares to €39.2 million, or basic and diluted loss per share of €1.16, for the fourth quarter of 2022 and €76.3 million, or basic and diluted loss per share of €2.27, for the full year of 2022.Met 101 miljoen verlies per jaar kan je nog zn goede kas hebben, maar moet er over 3 jaar
wederom geld bij.
En dan is er nog geen rekening gehouden met de kosten die gemaakt moeten worden om goedkeuring & vercommercialisering te kunnen uitvoeren.
Kortom ook hier zal de portomonee wederom open moeten bij de aandeelhouder. Over enkele jaren…. maar bij pharming is dit een mega probleem en een blok aan het dagelijks been. En bij de ander wordt het stilzwijgend niet gemeld?
Rare politiepet
ir.pharvaris.com/static-files/ec3bb03...